(Q40592020)

21 September 2017

title

Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group (English)

1 reference

21 September 2017

1 reference

4

0 references

Charles Erlichman

5

object named as

Charles Erlichman

1 reference

21 September 2017

Jan C Buckner

1

1 reference

21 September 2017

Joel M Reid

2

1 reference

21 September 2017

Keith Wright

3

1 reference

21 September 2017

Matthew Ames

6

1 reference

21 September 2017

Steve Cha

7

1 reference

21 September 2017

Judith R O'Fallon

8

1 reference

21 September 2017

Lawrence J Schaaf

9

1 reference

21 September 2017

Langdon L Miller

10

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

21 September 2017

1 reference

21 September 2017

volume

97

1 reference

21 September 2017

issue

9 Suppl

1 reference

21 September 2017

page(s)

2352-2358

1 reference

Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Chemotherapy for high-grade gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Chemotherapy of brain tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Irinotecan therapy in adults with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Effects of SN-38 (an active metabolite of CPT-11) on responses of human and rodent cells to irradiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Topoisomerase I inhibitors: review and update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Domains of human topoisomerase I and associated functions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Regulation of Xenopus laevis DNA topoisomerase I activity by phosphorylation in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11304

7 January 2021

Identifiers

DOI

10.1002/CNCR.11304

1 reference

21 September 2017

1 reference